Apellis Pharmaceuticals (apls 3.5 09/15/26)
13F holders, Q1 2026 (March 31)1holders −1
1new positions
0sold out
$1.06avg. 13F price*
At the end of Q1 2026, 1 institutions reported holding Apellis Pharmaceuticals (apls 3.5 09/15/26) in their 13F filings, down 1 from Q1 2024. 1 opened new positions and 0 sold out. The largest holder was Cantor Fitzgerald, L. P. ($1.2M).
- Company
- Apellis Pharmaceuticals (apls 3.5 09/15/26)
- CUSIP
- 03753UAB2
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $1.2M |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q1 2026: 1,130,000 shares bought, net +1,130,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Cantor Fitzgerald, L. P. | 0.04% | New | 1,130,000 | $1.2M |
"% of holder's portfolio" is APELLIS PHARMACEUTICALS (APLS 3.5 09/15/26)'s weight in each manager's 13F, not the share of Apellis Pharmaceuticals (apls 3.5 09/15/26) the manager owns.